Alkermes plc. Available-for-sale Securities, Debt Maturities, Amortized Cost Basis (Deprecated 2014-01-31)
Alkermes plc. (ALKS) had Available-for-sale Securities, Debt Maturities, Amortized Cost Basis (Deprecated 2014-01-31) of $577.38 million as of 2014-09-30, per its 10-Q filed 2014-10-29.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost · last filed 2014-10-29
- 2014-09-30: Available-for-sale Securities, Debt Maturities, Amortized Cost Basis (Deprecated 2014-01-31) $577.38M.
- 2014-06-30: Available-for-sale Securities, Debt Maturities, Amortized Cost Basis (Deprecated 2014-01-31) $522.57M.
- 2014-03-31: Available-for-sale Securities, Debt Maturities, Amortized Cost Basis (Deprecated 2014-01-31) $516.77M.
- 2013-12-31: Available-for-sale Securities, Debt Maturities, Amortized Cost Basis (Deprecated 2014-01-31) $249.84M.
| Period end | Available-for-sale Securities, Debt Maturities, Amortized Cost Basis (Deprecated 2014-01-31) | Available-for-sale Securities, Debt Maturities, Amortized Cost Basis (Deprecated 2014-01-31) as first filed |
|---|---|---|
| 2014-09-30 | $577.38M 10-Q · filed 2014-10-29 | |
| 2014-06-30 | $522.57M 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $516.77M 10-Q · filed 2014-04-30 | |
| 2013-12-31 | $249.84M 10-KT · filed 2014-02-27 | |
| 2013-09-30 | $202.65M 10-Q · filed 2013-10-31 | |
| 2013-06-30 | $206.74M 10-Q · filed 2013-07-25 | |
| 2013-03-31 | $204.96M 10-K · filed 2013-05-23 | |
| 2012-09-30 | $101.27M 10-Q · filed 2013-01-31 | $73.78M 10-Q · filed 2012-11-01 |
| 2012-06-30 | $138.58M 10-Q · filed 2012-07-26 | |
| 2012-03-31 | $154.65M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |